Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACD440 in Healthy Volunteers
NCT04704232Phase 1Completed
- Sponsor
- AlzeCure Pharma
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in neuropathic pain comparing ACD440 with Placebo (2 arms). Primary endpoint: Laser-evoked potentials at 5 days. Started Jan 2021; status: completed.
02
Drugs
acd440
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT04704232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704232.